{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:16:31Z","timestamp":1793308591494,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13311-023-01423-y","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T14:02:17Z","timestamp":1694008937000},"page":"1669-1681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy"],"prefix":"10.1016","volume":"20","author":[{"given":"Eleonora S.","family":"D'Ambrosio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1007\/s13311-023-01423-y_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.23810","article-title":"Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy","volume":"48","author":"Mendell","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-023-01423-y_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub3","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","volume":"1","author":"Manzur","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"10.1007\/s13311-023-01423-y_bib4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archneur.1987.00520200012009","article-title":"Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls","volume":"44","author":"Mendell","year":"1987","journal-title":"Arch Neurol."},{"issue":"10119","key":"10.1007\/s13311-023-01423-y_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"7894","key":"10.1007\/s13311-023-01423-y_bib6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"Prednisone in Duchenne muscular dystrophy","volume":"2","author":"Drachman","year":"1974","journal-title":"Lancet Lond Engl"},{"issue":"3 Pt 1","key":"10.1007\/s13311-023-01423-y_bib7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1212\/WNL.43.3_Part_1.532","article-title":"Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy","volume":"43","author":"Kissel","year":"1993","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01423-y_bib8","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.0000000000002147","article-title":"Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy","volume":"85","author":"Peverelli","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-023-01423-y_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","article-title":"Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy","volume":"91","author":"Silversides","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1007\/s13311-023-01423-y_bib10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid therapy and cardiac function in Duchenne muscular dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatr Cardiol"},{"issue":"9","key":"10.1007\/s13311-023-01423-y_bib11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","article-title":"All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy","volume":"61","author":"Schram","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1007\/s13311-023-01423-y_bib12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","article-title":"Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England","volume":"20","author":"Van Ruiten","year":"2016","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib13","first-page":"32","article-title":"Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study","volume":"145","author":"Siegel","year":"1974","journal-title":"IMJ Ill Med J."},{"issue":"8","key":"10.1007\/s13311-023-01423-y_bib14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archneur.1987.00520200016010","article-title":"Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone","volume":"44","author":"Brooke","year":"1987","journal-title":"Arch Neurol."},{"issue":"24","key":"10.1007\/s13311-023-01423-y_bib15","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"10.1007\/s13311-023-01423-y_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.43.3_Part_1.520","article-title":"Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)","volume":"43","author":"Griggs","year":"1993","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-023-01423-y_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0960-8966(02)00180-3","article-title":"High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy","volume":"12","author":"Connolly","year":"2002","journal-title":"Neuromuscul Disord NMD"},{"issue":"5","key":"10.1007\/s13311-023-01423-y_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-023-01423-y_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-8966(91)90099-E","article-title":"Steroids in Duchenne muscular dystrophy\u2013deflazacort trial","volume":"1","author":"Mesa","year":"1991","journal-title":"Neuromuscul Disord NMD"},{"issue":"4","key":"10.1007\/s13311-023-01423-y_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mus.880170405","article-title":"Deflazacort in Duchenne dystrophy: study of long-term effect","volume":"17","author":"Angelini","year":"1994","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1007\/s13311-023-01423-y_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscul Disord NMD"},{"issue":"9","key":"10.1007\/s13311-023-01423-y_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1007\/s13311-023-01423-y_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatr Neurol"},{"issue":"12","key":"10.1007\/s13311-023-01423-y_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mus.23831","article-title":"Corticosteroids in Duchenne muscular dystrophy: major variations in practice","volume":"48","author":"Griggs","year":"2013","journal-title":"Muscle Nerve"},{"issue":"20","key":"10.1007\/s13311-023-01423-y_bib26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pharmthera.2011.12.004","article-title":"Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor","volume":"134","author":"Clark","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1007\/s13311-023-01423-y_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","article-title":"Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes","volume":"134","author":"Hoffman","year":"2018","journal-title":"Steroids"},{"key":"10.1007\/s13311-023-01423-y_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"issue":"13","key":"10.1007\/s13311-023-01423-y_bib30","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-023-01423-y_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1007\/s13311-023-01423-y_bib33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1007\/s13311-023-01423-y_bib34","first-page":"950","article-title":"Somatic reversion\/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers","volume":"50","author":"Klein","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1007\/s13311-023-01423-y_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1083\/jcb.148.5.985","article-title":"Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion","volume":"148","author":"Lu","year":"2000","journal-title":"J Cell Biol."},{"issue":"11","key":"10.1007\/s13311-023-01423-y_bib36","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/pharmaceutics14112389","article-title":"Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on pediatric neurology","volume":"14","author":"Amanat","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1007\/s13311-023-01423-y_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"12","key":"10.1007\/s13311-023-01423-y_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1007\/s13311-023-01423-y_bib39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1007\/s13311-023-01423-y_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01423-y_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JND-170272","article-title":"Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history","volume":"5","author":"Kinane","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"26","key":"10.1007\/s13311-023-01423-y_bib44","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1007\/s13311-023-01423-y_bib45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"21","key":"10.1007\/s13311-023-01423-y_bib46","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1007\/s13311-023-01423-y_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-020-01106-1","article-title":"The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy","volume":"9","author":"Scaglioni","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1007\/s13311-023-01423-y_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1007\/s13311-023-01423-y_bib50","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01423-y_bib51","article-title":"Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study","author":"Clemens","year":"2023","journal-title":"J Neuromuscul Dis."},{"issue":"4","key":"10.1007\/s13311-023-01423-y_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"Oechsel","year":"2021","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1007\/s13311-023-01423-y_bib53","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajpath.2012.04.006","article-title":"Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino","volume":"181","author":"Wu","year":"2012","journal-title":"Am J Pathol"},{"issue":"7140","key":"10.1007\/s13311-023-01423-y_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1007\/s13311-023-01423-y_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS ONE"},{"issue":"10101","key":"10.1007\/s13311-023-01423-y_bib56","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1007\/s13311-023-01423-y_bib57","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s00415-023-11687-1","article-title":"Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015\u20132022): 2022 interim analysis","volume":"270","author":"Mercuri","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01423-y_bib58","unstructured":"Long-term outcomes of ataluren in Duchenne muscular dystrophy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179631 Available at: Accessed August 23, 2020"},{"issue":"6254","key":"10.1007\/s13311-023-01423-y_bib59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"issue":"5448","key":"10.1007\/s13311-023-01423-y_bib60","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"issue":"3685","key":"10.1007\/s13311-023-01423-y_bib61","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"issue":"6","key":"10.1007\/s13311-023-01423-y_bib62","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1007\/s13311-023-01423-y_bib63","first-page":"317","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"16","key":"10.1007\/s13311-023-01423-y_bib64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther"},{"issue":"25","key":"10.1007\/s13311-023-01423-y_bib65","doi-asserted-by":"crossref","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1007\/s13311-023-01423-y_bib66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2008","journal-title":"Nat Med"},{"issue":"9","key":"10.1007\/s13311-023-01423-y_bib67","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial.","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1007\/s13311-023-01423-y_bib68","unstructured":"B\u00f6nnemann CG, Belluscio BA, Braun S, et al. A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD. Presented at: ASGCT 25th Annual Meeting, May 16\u201319, 2022; Washington DC"},{"issue":"15","key":"10.1007\/s13311-023-01423-y_bib69","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1007\/s13311-023-01423-y_bib70","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.3390\/cells11192964","article-title":"CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"key":"10.1007\/s13311-023-01423-y_bib71","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"},{"issue":"6271","key":"10.1007\/s13311-023-01423-y_bib72","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"issue":"6410","key":"10.1007\/s13311-023-01423-y_bib73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"10.1007\/s13311-023-01423-y_bib74","article-title":"Unexpected death of a Duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-delivered CRISPR-transactivator","author":"Angela","year":"2023","journal-title":"medRxiv."},{"issue":"9","key":"10.1007\/s13311-023-01423-y_bib75","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of three prominent mutations in mouse and human models of Duchenne muscular dystrophy by single-cut genome editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"2","key":"10.1007\/s13311-023-01423-y_bib76","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat Med"},{"issue":"18","key":"10.1007\/s13311-023-01423-y_bib77","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1007\/s13311-023-01423-y_bib78","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124297","article-title":"AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice","volume":"3","author":"Hakim","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1007\/s13311-023-01423-y_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci Adv."},{"issue":"9","key":"10.1007\/s13311-023-01423-y_bib80","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/hum.2005.16.1047","article-title":"Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo","volume":"16","author":"Ren","year":"2005","journal-title":"Hum Gene Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01423-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923020056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923020056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:14:03Z","timestamp":1761808443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923020056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1878747923020056"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01423-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01423-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}